Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of CareStart G6PD rapid diagnostic test and CareStart G6PD biosensor in Mauritania

5 Aug 2021

Abstract excerpt

BACKGROUND: The elimination of Plasmodium vivax malaria requires 8-aminoquinolines, which are contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of acute haemolytic anaemia. Several point-of-care devices have been developed to detect G6PD deficiency. The objective of the present study was to evaluate the performance of two of these devices against G6PD genotypes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neonatal Health and Biochemistry
Share to Thyroid Disorders and Treatments

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 34353361
DOI: 10.1186/s40249-021-00889-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of CareStart G6PD rapid diagnostic test and CareStart G6PD biosensor in MauritaniaPMID 34353361Read ↗

Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood.Semantic proximity Read ↗

Diagnostic accuracy of the Point-of-Care Standard G6PD test™ (SD Biosensor) for Glucose-6-phosphate dehydrogenase deficiency: a systematic review of the literatureSemantic proximity Read ↗

Performance of the CareStart™ G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening.Semantic proximity Read ↗

Field Trial of the CareStart Biosensor Analyzer for the Determination of Glucose-6-Phosphate Dehydrogenase Activity in Haiti.Semantic proximity Read ↗

Prevalence of G6PD deficiency and diagnostic accuracy of a G6PD point-of-care test among a population at risk of malaria in Myanmar.Semantic proximity Read ↗

Prevalence of glucose-6-phosphate dehydrogenase deficiency (G6PDd), CareStart qualitative rapid diagnostic test performance, and genetic variants in two malaria-endemic areas in Sudan.Semantic proximity Read ↗

Quantitative G6PD point-of-care test can be used reliably on cord blood to identify male and female newborns at increased risk of neonatal hyperbilirubinaemia: a mixed method studySemantic proximity Read ↗

Assessment of Glucose-6 phosphate dehydrogenase deficiency in malaria suspected patients attending at Shele and Lante Health Center, Southern EthiopiaSemantic proximity Read ↗

Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health centre, Eastern EthiopiaSemantic proximity Read ↗

Prevalence of G6PD Deficiency and Distribution of Its Genetic Variants Among Malaria-Suspected Patients Visiting Metehara Health Center, Eastern EthiopiaSemantic proximity Read ↗

Optimizing Testing Time for Methaemoglobin Reduction Test in G6PD Screening: A Comparative Experimental Study between the Monica Cheesbrough Protocol and the Asutifi North District Hospital Protocol at Asutifi North District Hospital, Ghana.Semantic proximity Read ↗

Clinical Performance of the STANDARD™ G6PD Test in IndiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.